| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ghaith Al-Badri, Gian Marco Leggio, Giuseppe Musumeci, Rubina Marzagalli, Filippo Drago, Alessandro Castorin. Tackling dipeptidyl peptidase IV in neurological disorders. Neural regeneration research. vol 13. issue 1. 2020-10-01. PMID:29451201. |
dipeptidyl peptidase iv (dpp-iv) is a serine protease best known for its role in inactivating glucagon-like peptide-1 (glp-1), pituitary adenylate cyclase-activating polypeptide (pacap) and glucose-dependent insulinotropic peptide (gip), three stimulators of pancreatic insulin secretion with beneficial effects on glucose disposal. |
2020-10-01 |
2023-08-13 |
Not clear |
| Bahendeka Silver, Kaushik Ramaiya, Swai Babu Andrew, Otieno Fredrick, Sarita Bajaj, Sanjay Kalra, Bavuma M Charlotte, Karigire Claudine, Anthony Makhob. EADSG Guidelines: Insulin Therapy in Diabetes. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 9. issue 2. 2020-10-01. PMID:29508275. |
the preferred method of insulin initiation in t2dm is to begin by adding a long-acting (basal) insulin or once-daily premixed/co-formulation insulin or twice-daily premixed insulin, alone or in combination with glucagon-like peptide-1 receptor agonist (glp-1 ra) or in combination with other oral antidiabetic drugs (oads) (b). |
2020-10-01 |
2023-08-13 |
human |
| Jerry Meec. Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 9. issue 3. 2020-10-01. PMID:29574634. |
recent guidelines recommend two basic approaches for intensifying basal insulin: the use of rapid-acting insulin, either as additional prandial injections or as part of premix (biphasic) insulin; and the addition of glucagon-like peptide-1 receptor agonists (glp-1 ras) to the insulin therapy, which can be administered via subcutaneous injection once or twice daily, or weekly depending on formulation. |
2020-10-01 |
2023-08-13 |
Not clear |
| Jerry Meec. Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 9. issue 3. 2020-10-01. PMID:29574634. |
more recently, two fixed-ratio combinations of basal insulin and a glp-1 ra that allow for once-daily dosing have been approved. |
2020-10-01 |
2023-08-13 |
Not clear |
| Lawrence Blonde, Denis Raccah, Elisheva Lew, Juliana Meyers, Elena Nikonova, Mayank Ajmera, Keith L Davis, Monica Bertolini, Bruno Guerc. Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 9. issue 3. 2020-10-01. PMID:29675797. |
treatment intensification in type 2 diabetes: a real-world study of 2-oad regimens, glp-1 ras, or basal insulin. |
2020-10-01 |
2023-08-13 |
Not clear |
| Lawrence Blonde, Denis Raccah, Elisheva Lew, Juliana Meyers, Elena Nikonova, Mayank Ajmera, Keith L Davis, Monica Bertolini, Bruno Guerc. Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 9. issue 3. 2020-10-01. PMID:29675797. |
this retrospective analysis compared clinical and economic outcomes among patients with uncontrolled t2d initiating two oral antidiabetes drugs (oads), glucagon-like peptide-1 receptor agonists (glp-1 ras), or basal insulin in a real-world setting. |
2020-10-01 |
2023-08-13 |
Not clear |
| Ting-Ting Yin, Yan Bi, Ping Li, Shan-Mei Shen, Xiao-Lu Xiong, Li-Jun Gao, Can Jiang, Yan Wang, Wen-Huan Feng, Da-Long Zh. Comparison of Glycemic Variability in Chinese T2DM Patients Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 9. issue 3. 2020-10-01. PMID:29744819. |
it remains unclear, however, whether glp-1 receptor agonists or basal insulin has a better effect on glycemic variability in type 2 diabetes mellitus (t2dm) patients who are inadequately controlled by metformin. |
2020-10-01 |
2023-08-13 |
Not clear |
| Ting-Ting Yin, Yan Bi, Ping Li, Shan-Mei Shen, Xiao-Lu Xiong, Li-Jun Gao, Can Jiang, Yan Wang, Wen-Huan Feng, Da-Long Zh. Comparison of Glycemic Variability in Chinese T2DM Patients Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 9. issue 3. 2020-10-01. PMID:29744819. |
we used a continuous glucose monitoring system (cgms) to compare patients on a glp-1 receptor agonist with patients on basal insulin in terms of glycemic variability. |
2020-10-01 |
2023-08-13 |
Not clear |
| Eveline Bruinstroop, Laura Meyer, Catherine B Brouwer, Diana E van Rooijen, P Sytze van Da. Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 9. issue 3. 2020-10-01. PMID:29779196. |
insulin and the glp-1 receptor agonist liraglutide are both effective in reaching glycemic targets. |
2020-10-01 |
2023-08-13 |
Not clear |
| Baptist Gallwit. The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes - Is it Advantageous? European endocrinology. vol 10. issue 2. 2020-10-01. PMID:29872471. |
recently, the combination of glucagon-like peptide-1 (glp-1) receptor agonists and insulin has become available, which is associated with good efficacy and less risk for hypoglycaemia and weight gain. |
2020-10-01 |
2023-08-13 |
Not clear |
| Esben M Bech, Søren L Pedersen, Knud J Jense. Chemical Strategies for Half-Life Extension of Biopharmaceuticals: Lipidation and Its Alternatives. ACS medicinal chemistry letters. vol 9. issue 7. 2020-10-01. PMID:30034579. |
this viewpoint focuses on chemical moieties that convey protraction by albumin binding or by self-assembly to form larger structures, with glp-1 and insulin as examples. |
2020-10-01 |
2023-08-13 |
Not clear |
| Joel P Giblett, Sophie J Clarke, David P Dutka, Stephen P Hool. Glucagon-Like Peptide-1: A Promising Agent for Cardioprotection During Myocardial Ischemia. JACC. Basic to translational science. vol 1. issue 4. 2020-10-01. PMID:30167515. |
glucagon-like peptide-1-(7-36) amide (glp-1) is a human incretin hormone responsible for the release of insulin in response to food. |
2020-10-01 |
2023-08-13 |
human |
| Wen Pan, Yanan Zhang, Chun Zeng, Fen Xu, Jinhua Yan, Jianping Wen. miR-192 is upregulated in T1DM, regulates pancreatic β-cell development and inhibits insulin secretion through suppressing GLP-1 expression. Experimental and therapeutic medicine. vol 16. issue 3. 2020-10-01. PMID:30186503. |
mir-192 is upregulated in t1dm, regulates pancreatic β-cell development and inhibits insulin secretion through suppressing glp-1 expression. |
2020-10-01 |
2023-08-13 |
rat |
| Wen Pan, Yanan Zhang, Chun Zeng, Fen Xu, Jinhua Yan, Jianping Wen. miR-192 is upregulated in T1DM, regulates pancreatic β-cell development and inhibits insulin secretion through suppressing GLP-1 expression. Experimental and therapeutic medicine. vol 16. issue 3. 2020-10-01. PMID:30186503. |
western blot and reverse transcription-quantitative polymerase chain reaction analysis indicated that mir-192 suppressed the expression of glucagon-like peptide-1 (glp-1), a potent insulin secretagogue. |
2020-10-01 |
2023-08-13 |
rat |
| Louis S Matza, Kristina S Boye, Katie D Stewart, Rosirene Paczkowski, Jessica Jordan, Lindsey T Murra. Development of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ). Journal of patient-reported outcomes. vol 2. 2020-10-01. PMID:30294713. |
however, injectable medications other than insulin are increasingly used to treat type 2 diabetes, including glp-1 receptor agonists. |
2020-10-01 |
2023-08-13 |
Not clear |
| Kang-Hoon Kim, In-Seung Lee, Ji Young Park, Yumi Kim, Eun-Jin An, Hyeung-Jin Jan. Cucurbitacin B Induces Hypoglycemic Effect in Diabetic Mice by Regulation of AMP-Activated Protein Kinase Alpha and Glucagon-Like Peptide-1 via Bitter Taste Receptor Signaling. Frontiers in pharmacology. vol 9. 2020-10-01. PMID:30298009. |
cub ameliorated hyperglycemia by activating intestinal ampk levels and by inducing plasma glp-1 and insulin release in diabetic mice. |
2020-10-01 |
2023-08-13 |
mouse |
| Maja Baretić, Vesna Kušec, Ivana Pavlić-Rena. Glucagon-Like Peptide-1 Infusion Suppresses Aldosterone Levels in Healthy Normal-Weight Individuals: Double-Blind, Placebo-Controlled Crossover Study. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 9. issue 6. 2020-10-01. PMID:30298444. |
glucagon-like peptide-1 (glp-1) has many effects on the human body, but its glucose-lowering effect through its stimulation of insulin secretion is the most significant. |
2020-10-01 |
2023-08-13 |
human |
| Yaojing Jiang, Zhihong Wang, Bo Ma, Linling Fan, Na Yi, Bin Lu, Qinghua Wang, Rui Li. GLP-1 Improves Adipocyte Insulin Sensitivity Following Induction of Endoplasmic Reticulum Stress. Frontiers in pharmacology. vol 9. 2020-10-01. PMID:30459598. |
glp-1 improves adipocyte insulin sensitivity following induction of endoplasmic reticulum stress. |
2020-10-01 |
2023-08-13 |
Not clear |
| Yaojing Jiang, Zhihong Wang, Bo Ma, Linling Fan, Na Yi, Bin Lu, Qinghua Wang, Rui Li. GLP-1 Improves Adipocyte Insulin Sensitivity Following Induction of Endoplasmic Reticulum Stress. Frontiers in pharmacology. vol 9. 2020-10-01. PMID:30459598. |
glucagon-like peptide 1 (glp-1) improves insulin resistance of adipose tissue in obese humans. |
2020-10-01 |
2023-08-13 |
Not clear |
| Yaojing Jiang, Zhihong Wang, Bo Ma, Linling Fan, Na Yi, Bin Lu, Qinghua Wang, Rui Li. GLP-1 Improves Adipocyte Insulin Sensitivity Following Induction of Endoplasmic Reticulum Stress. Frontiers in pharmacology. vol 9. 2020-10-01. PMID:30459598. |
we hypothesized that glp-1 could directly improve insulin signaling in er-stressed adipocytes. |
2020-10-01 |
2023-08-13 |
Not clear |